Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
